PTO/SB/21 (08-03)
Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


# TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

| | |
|---|---|
| Application Number | 10/613,222 |
| Filing Date | July 3, 2003 |
| First Named Inventor | Rubinfeld |
| Art Unit | 1645 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 12636-330.201 |

Total Number of Pages in This Submission

## ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☑ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ After Allowance communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☑ Other Enclosure(s) (please Identify below):
  PTO/SB/08A, 16 references

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|---|---|
| Firm or Individual name | Maya Skubatch, Reg. No. 52,505<br>WILSON SONSINI GOODRICH & ROSATI<br>Customer No. 021971 |
| Signature | Maya Skubatch |
| Date | 12/5/03 |

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

| | | | |
|---|---|---|---|
| Typed or printed name | Tami O'Bryant | | |
| Signature | Tami O'Bryant | Date | 12/8/03 |

**PATENT**

**Attorney Docket No. 12636-330.201**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | |
|---|---|
| In re Application | PATENT APPLICATION |
| Inventor(s): Rubinfeld | Art Unit: 1645 |
| Application No.: 10/613,222 | Examiner: Unassigned |
| Filed: July 3, 2003 | |
| Title RESTORING CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION (AS AMENDED) | |

Mail Stop IDS
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under *37 C.F.R. §1.97*, subsection (b) because (check all that apply):

☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)

-- OR --

☐ (2) It is being filed within 3 months of entry of a national stage

-- OR --

☒ (3) It is being filed before the mail date of the first Office Action on the merits

-- OR --

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ *37 C.F.R. §1.97(c)*. If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; **or**

☐ a fee of $180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ *37 C.F.R. §1.97(d)*. If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of $130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization*. The Commissioner is hereby authorized to charge the above-referenced fees of $0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.12636-330.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: 12/4/03

By: _____
Maya Skubatch
Reg. No. 52,505

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Customer No. 021971

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449A/PTO | | | | Complete if Known | |
|---|---|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)* | | | | **Application No.** | 10/613,222 |
| | | | | **Filing Date** | July 3, 2003 |
| | | | | **First Named Inventor** | Rubinfeld |
| | | | | **Art Unit** | 1645 |
| | | | | **Examiner Name** | Unassigned |
| **Sheet** | **1** | **Of** | **2** | **Attorney Docket No.** | 12636-330.201 |

**OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS**

| Examiner Initials* | Cite No.[1] | Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published | T[2] |
|---|---|---|---|
| | | Debusscher et al., Phase I-II Trial of 5-AZA-2'-Deoxycytidine in Adult Patients with Acute Leukemia, *Leukemia Research,* Vol. 5, pp. 131-142, 1981 | |
| | | Kantarjian et al, Decitabine Studies in Chronic and Acute Myelogenous Leukemia, *Leukemia,* Vol. 11, Supp. 1, pp. S35-S36, 1997. | |
| | | Kantarjian et al., Results of Decitabine Therapy in the Accelerated and Blastic Phases of Chronic Myelogenous Leukemia, *Leukemia,* Vol. 11, Supp. 1, pp. 1617-1620, 1997. | |
| | | Koshy et al., 2-Deoxy 5-Azacytidine and Fetal Hemoglobin Induction in Sickle Cell Anemia, *Blood: The Journal of The American Society of Hematology,* Vol. 96, No. 7, pp. 2379-2384, 2000. | |
| | | Momparler et al, Clinical Trial on 5-AZA-2'-Deoxycytidine in Patients with Acute Leukemia, *Pharmac. Ther.*, Vol. 30, pp. 277-286, 1985. | |
| | | Momparler et al., 5-AZA-2'-Deoxycytidine Therapy in Patients with Acute Leukemia Inhibits DNA Methylation, *Leukemia Research,* Vol. 8, No. 2, pp. 181-185, 1984. | |
| | | Pinto et al., 5-AZA-2'-Deoxycytidine as a Differentiation Inducer in Acute Myeloid Lukaemias and Myelodysplastic Syndromes of the Elderly, *Bone Marrow Transplantation*, Vol. 4, Supp. 3, pp. 28-32, 1989. | |
| | | Pinto et al., 5-AZA-2'-Deoxycytidine as a Differentiation Inducer in Human Hemopoietic Malignancies: Preliminary Observations on the *in vivo* Modulation of Leukemia Cell Phenotype and Correlations with Clinical Response, *Leukemia Research*, Vol. 8, pp. 143-164, 1984 | |
| | | Rivard et al., Phase I Study on 5-AZA-2'-Deoxycytidine in Children with Acute Leukemia, *Leukemia Research*, Vol. 5, No. 6, pp. 453-462, 1981. | |
| | | Sacchi et al., Decitabine, a Hypomethylating Agent, is Active for the Treatment of Chronic Myelogenous Leukemia (CML) in Non-Lymphoid Blastic Phase (BP), *Blood: The Journal of The American Society of Hematology*, Vol. 92, No. 10, Supp. 1, pp. 252a, 1998. | |
| | | Schwartsmann et al., (5-AZA-2'-Deoxycytidine; DAC) Plus Daunorubicin as a First Line Treatment in Patients With Acute Myeloid Leukemia: Preliminary Observations, *Leukemia,* Vol. 11, Supp. 1, pp. S28-S31, 1997. | |
| | | Wijermans et al., Continuous Infusion of Low-Dose 5-AZA-2'-Deoxycytidine in Elderly Patients with High-Risk Myelodysplastic Syndrome, *Leukemia,* Vol. 11, Supp. 1, pp. 1-5, 1997. | |

| EXAMINER SIGNATURE | | DATE CONSIDERED | |
|---|---|---|---|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

| | | | | | |
|---|---|---|---|---|---|
| **Sheet** | **2** | **Of** | **2** | **Attorney Docket No.** | 12636-330.201 |

| ***Complete if Known*** | |
|---|---|
| **Application No.** | 10/613,222 |
| **Filing Date** | July 3, 2003 |
| **First Named Inventor** | Rubinfeld |
| **Art Unit** | 1645 |
| **Examiner Name** | Unassigned |

| **OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS** | | | |
|---|---|---|---|
| | | Wijermans et al., DNA Demethylating Therapy in MDS: The Experience with 5-AZA-2'-Deosycytidine (Decitabine), *Blood: The Journal of The American Society of Hematology*, Vol. 94, No. 16, Supp. 1, pp. 306a, 1999 | |
| | | Wijermans et al., Low-Dose 5-AZA-2'-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients, *Journal of Clinical Oncology*, Vol. 18, No. 5, pp. 956-962, 2000. | |
| | | Willemze et al., A Randomized Phase II Study on the Effects of 5-AZA-2'-Deoxycytidine Combined with Either Amsacrine or Idarubicin in Patients with Relapsed Acute Leukemia: an EORTC Leukemia Cooperative Group Phase II Study (06893), *Leukemia,* Vol. 11, Supp. 1, pp. S24-S27, 1997. | |
| | | Zagonel et al., 5-AZA-2'-Deoxycytidine (Decitabine) Induces Trilineage Response in Unfavourable Myelodysplastic Syndromes, *Leukemia,* Vol. 7, Supp. 1, pp. 30-35, 1993. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| EXAMINER SIGNATURE | | DATE CONSIDERED | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.